The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Hepatocellular Carcinoma: Etiology and Current and Future Drugs
Open accessAbstract
Hepatocellular carcinoma (HCC) is swiftly increasing in prevalence globally with a high mortality rate. The progression of HCC in patients is induced with advanced fibrosis, mainly cirrhosis, and hepatitis. The absence of proper preventive or curative treatment methods encouraged extensive research against HCC to develop new therapeutic strategies. The Food and Drug Administration-approved Nexavar (sorafenib) is used in the treatment of patients with unresectable HCC. In 2017, Stivarga (regorafenib) and Opdivo (nivolumab) got approved for patients with HCC after being treated with sorafenib, and in 2018, Lenvima (lenvatinib) got approved for patients with unresectable HCC. But, owing to the rapid drug resistance development and toxicities, these treatment options are not completely satisfactory. Therefore, there is an urgent need for new systemic combination therapies that target different signaling mechanisms, thereby decreasing the prospect of cancer cells developing resistance to treatment. In this review, HCC etiology and new therapeutic strategies that include currently approved drugs and other potential candidates of HCC such as Milciclib, palbociclib, galunisertib, ipafricept, and ramucirumab are evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · cited 1×
“9 months.(116) A list of currently approved drugs by the FDA for the treatment of HCC is given in table 2.”
BackgroundMalumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Tumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Muñoz, A., & Thomas, D. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11913-1 · Cited by 1,099
Epidemiology of Hepatocellular Carcinoma: Consider the Population
Mittal, S., & El-Serag, H. B. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182872f29 · Cited by 1,076
Immune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Statements from the Taormina expert meeting on occult hepatitis B virus infection
Raimondo, G., Allain, J.-P., Brunetto, M. R., Buendia, M.-A., Chen, D.-S., Colombo, M., Craxì, A., Donato, F., Ferrari, C., Gaeta, G. B., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.014 · Cited by 833
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
Arzumanyan, A., Reis, H. M. G. P. V., & Feitelson, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3449 · Cited by 800
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis
Rowe, J., Ghouri, Y., & Mian, I. (2017) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_9_16 · Cited by 719
Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A. (2015) · Molecules · doi:10.3390/molecules200916852 · Cited by 716
Occult Hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver Disease
Cacciola, I., Pollicino, T., Squadrito, G., Cerenzia, G., Orlando, M. E., & Raimondo, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410104 · Cited by 666
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
El-Serag, H. B., & Kanwal, F. (2014) · Hepatology · doi:10.1002/hep.27222 · Cited by 646
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Giovannini, C., Croce, C. M., Bolondi, L., et al. (2008) · Oncogene · doi:10.1038/onc.2008.178 · Cited by 639
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625
Anido, J., Sáez-Borderías, A., Gonzàlez-Juncà, A., Rodón, L., Folch, G., Carmona, M. A., Prieto-Sánchez, R. M., Barba, I., Martínez-Sáez, E., Prudkin, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.023 · Cited by 572
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Donato, F., Boffetta, P., & Puoti, M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980130)75:3<347::aid-ijc4>3.0.co;2-2 · Cited by 543
The changing pattern of epidemiology in hepatocellular carcinoma
Nordenstedt, H., White, D. L., & El-Serag, H. B. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60507-5 · Cited by 535
Torbenson, M., & Thomas, D. L. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00345-6 · Cited by 533
Peñuelas, S., Anido, J., Prieto-Sánchez, R. M., Folch, G., Barba, I., Cuartas, I., García-Dorado, D., Poca, M. A., Sahuquillo, J., Baselga, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.011 · Cited by 526
The Etiology of Hepatocellular Carcinoma and Consequences for Treatment
Sanyal, A. J., Yoon, S. K., & Lencioni, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s4-14 · Cited by 517
Rossi, A. G., Sawatzky, D. A., Walker, A., Ward, C., Sheldrake, T. A., Riley, N. A., Caldicott, A., Martinez-Losa, M., Walker, T. R., Duffin, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1468 · Cited by 509
Yamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507 · cited 3×
“Its higher potency than sorafenib in targeting FGF1– and FGF-2–orchestrated angiogenesis makes it a promising candidate for HCC.(102) Other targets of lenvatinib include VEGFR3, KIT, RET and PDGF receptor a.”
BackgroundInfluentialMultiple levels of cyclin specificity in cell-cycle control
Bloom, J., & Cross, F. R. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2105 · Cited by 503
Cyclin-dependent kinases: a family portrait
Malumbres, M., Harlow, E., Hunt, T., Hunter, T., Lahti, J. M., Manning, G., Morgan, D. O., Tsai, L.-H., & Wolgemuth, D. J. (2009) · Nature Cell Biology · doi:10.1038/ncb1109-1275 · Cited by 495
Sorafenib: A Review of its Use in Advanced Hepatocellular Carcinoma
Keating, G. M., & Santoro, A. (2009) · Drugs · doi:10.2165/00003495-200969020-00006 · Cited by 482
The Global Epidemiology of Hepatocellular Carcinoma: Present and Future
McGlynn, K. A., & London, W. T. (2011) · Clinics in Liver Disease · doi:10.1016/j.cld.2011.03.006 · Cited by 471
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Mechanisms of HBV-related hepatocarcinogenesis
Neuveut, C., Wei, Y., & Buendia, M. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.033 · Cited by 421
Liu, S., Zhang, H., Gu, C., Yin, J., He, Y., Xie, J., & Cao, G. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp180 · Cited by 388
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Ikeda, K., Kudo, M., Kawazoe, S., Osaki, Y., Ikeda, M., Okusaka, T., Tamai, T., Suzuki, T., Hisai, T., Hayato, S., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-016-1263-4 · Cited by 338
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients
Jiang, Z., Jhunjhunwala, S., Liu, J., Haverty, P. M., Kennemer, M. I., Guan, Y., Lee, W., Carnevali, P., Stinson, J., Johnson, S., et al. (2012) · Genome Research · doi:10.1101/gr.133926.111 · Cited by 324
Hepatitis B and hepatocellular carcinoma #
Di Bisceglie, A. M. (2009) · Hepatology · doi:10.1002/hep.22962 · Cited by 321
Increasing burden of liver disease in patients with HIV infection
Joshi, D., O'Grady, J., Dieterich, D., Gazzard, B., & Agarwal, K. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62001-6 · Cited by 305
Innate and adaptive immune responses in HCV infections
Heim, M. H., & Thimme, R. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.06.035 · Cited by 305
Intratumor Heterogeneity in Hepatocellular Carcinoma
Friemel, J., Rechsteiner, M., Frick, L., Böhm, F., Struckmann, K., Egger, M., Moch, H., Heikenwalder, M., & Weber, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0122 · Cited by 296
Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C. B., Roberto, M. P., Tovar, V., Sia, D., Molina-Sánchez, P., Nguyen, C. B., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312268 · Cited by 291
Cell cycle regulation by long non-coding RNAs
Kitagawa, M., Kitagawa, K., Kotake, Y., Niida, H., & Ohhata, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1423-0 · Cited by 278
Aflatoxins as a cause of hepatocellular carcinoma.
Kew, M. C. (2013) · PubMed · Cited by 263
Bruix, J., Tak, W.-Y., Gasbarrini, A., Santoro, A., Colombo, M., Lim, H.-Y., Mazzaferro, V., Wiest, R., Reig, M., Wagner, A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.028 · Cited by 254
Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28
Le, P. N., McDermott, J. D., & Jimeno, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.005 · Cited by 253
Hardee, M. E., Marciscano, A. E., Medina-Ramirez, C. M., Zagzag, D., Narayana, A., Lonning, S. M., & Barcellos-Hoff, M. H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0546 · Cited by 246
Huang, Y.-T., Jen, C.-L., Yang, H.-I., Lee, M.-H., Su, J., Lu, S.-N., Iloeje, U. H., & Chen, C.-J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2335 · Cited by 229
Risk of HCC: Genetic heterogeneity and complex genetics
Dragani, T. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.015 · Cited by 228
Obesity and diabetes as a risk factor for hepatocellular carcinoma
Regimbeau, J. M., Colombat, M., Mognol, P., Durand, F., Abdalla, E., Degott, C., Degos, F., Farges, O., & Belghiti, J. (2004) · Liver Transplantation · doi:10.1002/lt.20033 · Cited by 227
Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 221
Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma
Wu, X., Xie, G., & Chen, D. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04997.x · Cited by 212
Jimeno, A., Gordon, M., Chugh, R., Messersmith, W., Mendelson, D., Dupont, J., Stagg, R., Kapoun, A. M., Xu, L., Uttamsingh, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2157 · Cited by 209
Hojjat-Farsangi, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813768 · Cited by 203
Viral hepatitis and HIV co-infection
Soriano, V., Vispo, E., Labarga, P., Medrano, J., & Barreiro, P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.021 · Cited by 197
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Zhai, B. (2013) · World Journal of Hepatology · doi:10.4254/wjh.v5.i7.345 · Cited by 183
Weltman, M. D., Brotodihardjo, A., Crewe, E. B., Farrell, G. C., Bililus, M., Grierson, J. M., & Liddle, C. (1995) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.1995.tb00070.x · Cited by 182
Effects of hepatitis B virus X protein on the development of liver cancer
Zhang, X., Zhang, H., & Ye, L. (2006) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.10.003 · Cited by 181
Hepatitis C virus-induced hepatocarcinogenesis
Bartosch, B., Thimme, R., Blum, H. E., & Zoulim, F. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.008 · Cited by 178
Hepatitis C virus-induced hepatocellular carcinoma
Goossens, N., & Hoshida, Y. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.2.105 · Cited by 172
Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis
Shen, H.-M., & Ong, C.-N. (1996) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/s0165-1110(96)90005-6 · Cited by 171
Fornari, F., Pollutri, D., Patrizi, C., La Bella, T., Marinelli, S., Casadei Gardini, A., Marisi, G., Baron Toaldo, M., Baglioni, M., Salvatore, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1464 · Cited by 168
Viral hepatitis and hepatocellular carcinoma: etiology and management
Zamor, P. J., deLemos, A. S., & Russo, M. W. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.03.14 · Cited by 165
Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma
Vescovo, T., Refolo, G., Vitagliano, G., Fimia, G. M., & Piacentini, M. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.07.019 · Cited by 163
Zhu, A. X., Finn, R. S., Mulcahy, M., Gurtler, J., Sun, W., Schwartz, J. D., Dalal, R. P., Joshi, A., Hozak, R. R., Xu, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1442 · Cited by 159
Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations
Wong, R. J., & Ahmed, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i5.263 · Cited by 139
Weil, R., Sirma, H., Giannini, C., Kremsdorf, D., Chable-Bessia, C., Dargemont, C., Bréchot, C., & Israël, A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6345 · Cited by 129
Non-ATP Competitive Protein Kinase Inhibitors
Garuti, L., Roberti, M., & Bottegoni, G. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791859333 · Cited by 128
Albert, T., Rigault, C., Eickhoff, J., Baumgart, K., Antrecht, C., Klebl, B., Mittler, G., & Meisterernst, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12408 · Cited by 124
Cho, L. Y., Yang, J. J., Ko, K., Park, B., Shin, A., Lim, M. K., Oh, J., Park, S., Kim, Y. J., Shin, H., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25321 · Cited by 120
Targeting cell cycle and apoptosis for the treatment of human malignancies
Senderowicz, A. M. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.09.014 · Cited by 119
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 110
Sirma, H., Weil, R., Rosmorduc, O., Urban, S., Israël, A., Kremsdorf, D., & Bréchot, C. (1998) · Oncogene · doi:10.1038/sj.onc.1201737 · Cited by 106
STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Tai, W., Chu, P., Shiau, C., Chen, Y., Li, Y.-S., Hung, M., Chen, L., Chen, P., Su, J., Lin, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0725 · Cited by 101
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations
Bisteau, X., Caldez, M. J., & Kaldis, P. (2014) · Cancers · doi:10.3390/cancers6010079 · Cited by 99
Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma
Gabr, A., Abouchaleh, N., Ali, R., Baker, T., Caicedo, J. C., Katariya, N., Abecassis, M. M., Riaz, A., Lewandowski, R. J., & Salem, R. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.06.027 · Cited by 98
Established and Novel Cdk/Cyclin Complexes Regulating the Cell Cycle and Development
Gopinathan, L., Ratnacaram, C. K., & Kaldis, P. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-19065-0_16 · Cited by 93
Choudhari, S. R., Khan, M. A., Harris, G., Picker, D., Jacob, G. S., Block, T., & Shailubhai, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0561 · Cited by 90 · cited 1×
“222 © 2019 Indian National Associa HCV can cause chronic infections that trigger the PI3K/ Akt/STAT3 pathway in tumor cells.(23)”
BackgroundSelf-citationBasu, S., & Bhattacharyya, S. N. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku346 · Cited by 85
Tang, S., Tan, G., Jiang, X. L., Han, P., Zhai, B., Dong, X., Qiao, H., Jiang, H., & Sun, X. (2016) · Oncotarget · doi:10.18632/oncotarget.12304 · Cited by 85
Acknowledging Patient Heterogeneity in Economic Evaluation: A Systematic Literature Review
Grutters, J. P. C., Sculpher, M., Briggs, A. H., Severens, J. L., Candel, M. J. J. M., Stahl, J. E., Ruysscher, D. D., Boer, A., Ramaekers, B. L. T., & Joore, M. A. (2013) · PharmacoEconomics · doi:10.1007/s40273-012-0015-4 · Cited by 82
Carr, B. I., Cavallini, A., Lippolis, C., D’Alessandro, R., Messa, C., Refolo, M. G., & Tafaro, A. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24148 · Cited by 74
Azumi, J., Tsubota, T., Sakabe, T., & Shiota, G. (2016) · Cancer Science · doi:10.1111/cas.13006 · Cited by 74
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Schöffski, P., Gordon, M. S., Smith, D. C., Kurzrock, R., DAUD, A. I., Vogelzang, N. J., Lee, Y., Scheffold, C., & Shapiro, G. I. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.011 · Cited by 73
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2016) · Liver Cancer · doi:10.1159/000449342 · Cited by 70
HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level
Ayub, A., Ashfaq, U. A., & Haque, A. (2013) · BioMed Research International · doi:10.1155/2013/810461 · Cited by 69
Hsieh, F., Chen, Y., Hung, M., Chu, P., Tsai, M., Chen, L., Hsiao, Y., Shih, C., Chang, M.-J., Chao, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12072 · Cited by 69
Liu, X., Shi, S., Lam, F., Pepper, C. J., Fischer, P. M., & Wang, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.26127 · Cited by 67
Albanese, C., Alzani, R., Amboldi, N., Avanzi, N. R., Ballinari, D., Brasca, M. G., Festuccia, C., Fiorentini, F., Locatelli, G., Pastori, W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0190 · Cited by 66
How do persistent infections with hepatitis C virus cause liver cancer?
Mitchell, J. K., Lemon, S. M., & McGivern, D. R. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.09.003 · Cited by 64
Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas
Riener, M., Fritzsche, F. R., Soll, C., Pestalozzi, B. C., Probst-Hensch, N. M., Clavien, P., Jochum, W., Soltermann, A., Moch, H., & Kristiansen, G. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03527.x · Cited by 63
(2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.08.001 · Cited by 61
Fung, J., Lai, C., But, D. Y.-K., Wong, D. K.-H., Cheung, T.-K., & Yuen, M. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01751.x · Cited by 58
Lam, F., Abbas, A. Y., Shao, H., Teo, T., Adams, J., Li, P., Bradshaw, T. D., Fischer, P. M., Walsby, E. J., Pepper, C. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2296 · Cited by 55
Maier, A., Peille, A.-L., Vuaroqueaux, V., & Lahn, M. M. F. (2015) · Cellular Oncology · doi:10.1007/s13402-014-0210-8 · Cited by 51
Rui, R., Lou, J., Zou, L., Zhong, R., Wang, J., Ding, X., Wang, Q., Li, H., Wu, J., Lu, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044522 · Cited by 47
Ramaekers, B. L. T., Joore, M. A., & Grutters, J. P. C. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.013 · Cited by 47
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma
Eggert, T., & Greten, T. F. (2017) · Digestion · doi:10.1159/000464282 · Cited by 45
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181af5e35 · Cited by 43
Cabozantinib : modalités d’action, efficacité et indications
Cochin, V., Gross‐Goupil, M., Ravaud, A., Godbert, Y., & Moulec, S. L. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.03.013 · Cited by 42
Nakazawa, Y., Kawano, S., Matsui, J., Funahashi, Y., Tohyama, O., Muto, H., Nakagawa, T., & Matsushima, T. (2014) · Cancer Science · doi:10.1111/cas.12581 · Cited by 40
Chen, W., Xiao, W., Zhang, K., Yin, X., Lai, J., Liang, L., & Dong, C. (2016) · Scientific Reports · doi:10.1038/srep22976 · Cited by 38
Paiva, C. J., Godbersen, J. C., Soderquist, R. S., Rowland, T., Kilmarx, S. E., Spurgeon, S. E. F., Brown, J. R., Srinivasa, S. P., & Danilov, A. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143685 · Cited by 37
Brown, A. S., & Goodman, Z. D. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.4 · Cited by 36
Aspeslagh, S., Shailubhai, K., Bahleda, R., Gazzah, A., Varga, A., Hollebecque, A., Massard, C., Spreafico, A., Reni, M., & Soria, J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3303-z · Cited by 34
Self-citationRangwala, F. A., Williams, K. P., Smith, G. R., Thomas, Z., Allensworth, J. L., Lyerly, H. K., Diehl, A. M., Morse, M. A., & Devi, G. R. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-402 · Cited by 33
Hepatitis C Virus and Hepatocellular Carcinoma
Kanda, T., Yokosuka, O., & Omata, M. (2013) · Biology · doi:10.3390/biology2010304 · Cited by 31
Haider, C., Grubinger, M., Řezníčková, E., Weiß, T. S., Rotheneder, H., Miklos, W., Berger, W., Jorda, R., Zatloukal, M., Gucký, T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0263 · Cited by 29
Inherited hepatocellular carcinoma
Villanueva, A., Newell, P., & Hoshida, Y. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.07.008 · Cited by 28
Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas
Hashimoto, M., Tashiro, H., Kobayashi, T., Kuroda, S., Hamaoka, M., & Ohdan, H. (2017) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-017-1589-2 · Cited by 24
Deng, L.-F., Ren, Z., Jia, Q., Wu, W., Shen, H., & Wang, Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-363 · Cited by 22
Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells
Liu, T., Liu, R., Zhang, S., Guo, K., Zhang, Q., Li, W., & Liu, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6177 · Cited by 20
Bagi, C. M., Gebhard, D. F., & Andresen, C. J. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328350916f · Cited by 19
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83
Liu, X., Lam, F., Shi, S., Fischer, P. M., & Wang, S. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9641-5 · Cited by 14
Current status of multimodal & combination therapy for hepatocellular carcinoma.
Yang, J. H., Yan, L., & Wang, W. (2012) · PubMed · Cited by 12
Cited by
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Immunotherapy for hepatocellular carcinoma
Zongyi, Y., & Xiaowu, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.12.002 · Cited by 265
Metadata
- Authors
- Jindal, A., Thadi, A., & Shailubhai, K.
- Venue
- Journal of Clinical and Experimental Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 9
- Issue
- 2
- Pages
- 221-232
- ISSN
- 0973-6883 (ISSN-L)
- OpenAlex
- W2912201468
- Cited by
- 257
- References
- 124
- FWCI
- 20.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.